Neumora Therapeutics (NMRA) Net Cash Flow (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Net Cash Flow of -$35.5 million for Q1 2026, down 131.93% year-over-year from $111.0 million in Q1 2025, and down 166.33% quarter-over-quarter from $53.5 million in Q4 2025.
Neumora Therapeutics (NMRA) Net Cash Flow (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Net Cash Flow history runs 5 years deep, the most recent figure standing at -$35.5 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 131.93% year-over-year to -$35.5 million; the TTM figure through Mar 2026 stood at $19.0 million (up 133.89% YoY), while the FY2025 annual figure was $39.2 million, up 116.89% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$35.5 million, down from $53.5 million in the prior quarter.
- The five-year high for Net Cash Flow was $208.1 million in Q3 2023, with the low at -$191.1 million in Q1 2024.
- The 5-year median for Net Cash Flow is -$13.4 million (2022), against an average of -$7.6 million.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow plunged 534.44% in 2024, then soared 140.02% in 2025.
- Neumora Therapeutics' Net Cash Flow stood at -$11.6 million in 2022, then slumped by 230.76% to -$38.2 million in 2023, then sank by 249.23% to -$133.6 million in 2024, then jumped by 140.02% to $53.5 million in 2025, then plunged by 166.33% to -$35.5 million in 2026.
- Business Quant data shows NMRA's Net Cash Flow at -$35.5 million in Q1 2026, $53.5 million in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | -35.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.46 Mn |
| Mar 31, 2026 | -35.46 Mn |
| Dec 31, 2025 | 53.46 Mn |
| Dec 31, 2025 | 53.46 Mn |
| Sep 30, 2025 | 4.55 Mn |
| Sep 30, 2025 | 4.55 Mn |
| Jun 30, 2025 | -3.55 Mn |
| Jun 30, 2025 | -3.55 Mn |
| Mar 31, 2025 | -15.29 Mn |
| Mar 31, 2025 | -15.29 Mn |
| Dec 31, 2024 | -133.57 Mn |
| Dec 31, 2024 | -133.57 Mn |
| Sep 30, 2024 | 125.04 Mn |
| Sep 30, 2024 | 125.04 Mn |
| Jun 30, 2024 | -32.25 Mn |
| Jun 30, 2024 | -32.25 Mn |
| Mar 31, 2024 | -191.11 Mn |
| Mar 31, 2024 | -191.11 Mn |
| Dec 31, 2023 | -38.25 Mn |
| Dec 31, 2023 | -38.25 Mn |